Neurochemical pathogenesis of fibromyalgia

Zeitschrift fur Rheumatologie

Volumn 57, Issue SUPPL. 2, 1998, Pages 63-66

  Russell, I J ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Allodynia; Fibromyalgia; Pathogenesis; Serotonin; Substance P

Indexed keywords

NEUROTRANSMITTER; SEROTONIN; SUBSTANCE P;

ALLODYNIA; ANIMAL EXPERIMENT; CLINICAL RESEARCH; CONFERENCE PAPER; FIBROMYALGIA; NEUROCHEMISTRY; NEUROMODULATION; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PAIN THRESHOLD; PATHOGENESIS;

EID: 0032424551     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003930050238     Document Type: Conference Paper

References (35)

1. Almay BG, Johansson F, von Knorring L, Le Greves P, Terenius L (1988) Substance P in CSF of patients with chronic pain syndromes. Pain 33:3-9
2. Becquet D, Faudon M, Hery F (1990) The role of serotonin release and autoreceptors in the dorsalis raphe nucleus in the control of serotonin release in the cat caudate nucleus. Neuroscience 39:639-647
3. Bonica JJ (1990) Definitions and Taxonomy of Pain, in: Bonica JJ, Loeser JD, Chapman CR, Fordyce WE (eds) The Management of Pain, Vol I. 2 ed. Philadelphia: Lea & Febiger, pp 18-27
4. Bradley LA, Alberts KR, Alarcon GS, et al. (1996) Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM). (Abstract) Arthritis Rheum 39 (Suppl):S212
5. Carstens ME, Engelbrecht AH, Russell VA, Aalbers C, Gagiano CA, Chalton DO, Taljaard JJF (1986) Imipramine binding sites on platelets of patients with major depressive disorder. Psych Res 18:333-342
6. Eide PK, Hole K (1991) Interactions between serotonin and substance P in the spinal regulation of nociception. Brain Res 550:225-230
7. Gibson SJ, Littlejohn GO, Gorman MM, Helme Rd, Granges G (1994) Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain 58:185-193
8. Guieu R, Tardy-Gervet MF, Giraud P, Boudouresque F (1993) (Met-enkephalin and substance P. Comparison of CSF levels in patients with chronic pain based on a sampling procedure). (In French). Revue Neurologique 149:398-401
9. Hoheisel U, Mense S, Ratkai M (1996) Effects of spinal cord superfusion with substance P on the excitability of rat dorsal horn neurons processing input from deep tissues. J Musculoske Pain 3(3):23-43
10. Hornfeldt CS, Sun X, Larson AA (1994) The NH2-terminus of substance P modulates NMDA-induced activity in the mouse spinal cord. J Neurosci 14:3364-3369
11. Hrycaj P, Stratz T, Müller W (1993) Platelet 3H-imipramine uptake receptor density and serum serotonin in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 20:1986-1987
12. Jacobsen S, Danneskiold-Samsoe B, Lund B (eds) (1993) Musculoskeletal pain, myofascial pain syndrome and the fibromyalgia syndrome: Proceedings from the Second World Congress on Myofascial Pain and Fibromyalgia. J Musculoske Pain 1(3/4):1-313
13. Johnson M, Hanson GR, Gibb JW, Adair J, Filloux F (1994) Effect of neonatal hypoxia-ischemia on nigro-striatal dopamine receptors and on striatal neuropeptide Y, dynorphin A and substance P concentrations in rats. Brain Res Dev Brain Res 83:109-118
14. Kang Y-K, Russell IJ, Vipraio GA, Acworth IN (1998) Low urinary 5-hydroxyindole acetic acid in fibromyalgia syndrome: Evidence in support of A serotonin-deficiency pathogenesis. Myalgia (A new French journal) 1: (in press)
15. Malmberg AB, Yaksh TL (1992) Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 257:1276-1279
16. Mejia JA, Pernow J, von Holst H, Rudehill A, Lundberg JM (1988) Effects of neuropeptide Y, culcitonin gene-related peptide, substance P, and capsaicin on cerebral arteries in man and animals. J Neurosurg 69:913-918
17. Moldofsky H (1982) Rheumatic pain modulation syndrome: The interrelationships between sleep, central nervous system, serotonin and pain. Adv Neurol 33:51-57
18. Moldofsky H, Warsh JJ (1978) Plasma tryptophan and musculoskeletal pain in nonarticular rheumatism ("fibrositis syndrome"). Pain 5:65-71
19. Murphy RM, Zemlan FP (1987) Differential effects of substance P on serotonin-modulated spinal nociceptive reflexes. Psychopharmacology (Berlin) 93:118-121
20. Nyberg F, Liu Z, Lind C, et al. (1995) Enhanced CSF levels of substance P in patients with painful arthrosis but not in patients with pain from herniated lumbar discs. (Abstract) J Musculoske Pain 3(Suppl 1):2
21. Reynolds WJ, Chiu B, Inman RD (1988) Plasma substance P levels in fibrositis. J Rheumatol 15:1802-1803
22. Russell IJ (1996) Neurochemical pathogenesis of fibromyalgia syndrome. J Musculoske Pain 1(1&2):61-92
23. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Javors MA, Bowden CA (1992) Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 19:104-109
24. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Wall K (1989) Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol 19 (Suppl): 158-163
25. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F (1995) Elevated cerebrospinal levels of substance P patients fibromyalgia syndrome. Arthritis Rheum 37:1593-1601
26. Russell IJ, Vaeroy H, Javors M, Nyberg F (1992) Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 35:550-556
27. Russell IJ, Vipraio GA, Acworth I (1993) Abnormalities in the central nervous system (CNS) metabolism of tryptophan (TRY) to 3-hydroxy kynurenine (OHKY) in fibromyalgia syndrome (FS). (Abstract) Arthritis Rheum 36(9): S222
28. Sharma HS, Nyherg F, Olsson Y, Dey PK (1990) Alteration of substance P after trauma to the spinal cord: An experimental study in the rat. Neuroscience 38:205-212
29. Sjostrom S, Tamsen A, Hartvig P, Folkesson R, Terenius L (1988) Cerebrospinal fluid concentrations of substance P and (met)enkephalin-Arg6-Phe7 during surgery and patient-controlled analgesia. Anesth Analg 67:976-981
30. Tsigos C, Diemel LT, Tomlinson DR, Young RJ (1993) Cerebrospinal fluid levels of substance P and calcitoningene-related peptide: Correlation with sural nerve levels and neuropathic signs in sensory diabetic polyneuropathy. Clinical Sci 84:305-311
31. Vaeroy H, Helle R, Forre O, Kass E, Terenius L (1988) Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: New features for diagnosis. Pain 32:21-26
32. Walker PD, Riley LA, Hart RP, Jonakait GM (1991) Serotonin regulation of tachykinin biosynthesis in the rat neostriatum. Brain Res 546:33-39
33. Welin M, Bragee B, Nyberg K et al. (1995) Elevated substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in esf from fibromyalgia patients. (Abstract) J Musculoske Pain 3(Suppl 1):4
34. Wolfe F, Russell IJ, Vipraio GA, Ross K, Anderson J (1997) Serotonin levels, pain threshold, and FM. J Rheumatol 24:555-559
35. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al. (1990) The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis Rheum 33:160-172